| 2.32 0.02 (0.87%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.21 |
1-year : | 3.57 |
| Resists | First : | 2.75 |
Second : | 3.05 |
| Pivot price | 2.59 |
|||
| Supports | First : | 2.26 |
Second : | 1.88 |
| MAs | MA(5) : | 2.41 |
MA(20) : | 2.64 |
| MA(100) : | 4.42 |
MA(250) : | 6.06 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 4 |
D(3) : | 7.1 |
| RSI | RSI(14): 33.4  |
|||
| 52-week | High : | 10.78 | Low : | 2.26 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TMCI ] has closed above bottom band by 7.0%. Bollinger Bands are 55.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 41 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.36 - 2.38 | 2.38 - 2.39 |
| Low: | 2.23 - 2.25 | 2.25 - 2.26 |
| Close: | 2.3 - 2.32 | 2.32 - 2.34 |
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.
Fri, 23 Jan 2026
Treace Medical Concepts, Inc. (TMCI) Stock Analysis: Exploring A Potential 81% Upside - DirectorsTalk Interviews
Fri, 23 Jan 2026
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Receives Average Rating of "Reduce" from Brokerages - MarketBeat
Tue, 13 Jan 2026
Treace Medical Concepts Reports Preliminary 2025 Revenue Results and Updates on Surgeon Adoption Trends - Quiver Quantitative
Wed, 07 Jan 2026
The Analyst Verdict: Treace Medical Concepts In The Eyes Of 6 Experts - Benzinga
Wed, 07 Jan 2026
Why Investors Shouldn't Be Surprised By Treace Medical Concepts, Inc.'s (NASDAQ:TMCI) Low P/S - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 64 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 25.3 (%) |
| Held by Institutions | 61.2 (%) |
| Shares Short | 3,170 (K) |
| Shares Short P.Month | 3,720 (K) |
| EPS | -0.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.39 |
| Profit Margin | -22.9 % |
| Operating Margin | -29.3 % |
| Return on Assets (ttm) | -14.8 % |
| Return on Equity (ttm) | -51.7 % |
| Qtrly Rev. Growth | 11.3 % |
| Gross Profit (p.s.) | 2.74 |
| Sales Per Share | 3.43 |
| EBITDA (p.s.) | -0.62 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -2.9 |
| PEG Ratio | 0 |
| Price to Book value | 1.65 |
| Price to Sales | 0.67 |
| Price to Cash Flow | -12.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|